企業プロフィール
Soleno Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- SLNO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
53.01 USD (+0.04%)
終値
最終更新: 2026年5月15日
2.76B USD
時価総額
株価変動の要因
Current closing-price context is not available for SLNO.
企業概要
Prader-Willi Syndrome Focus
Soleno Therapeutics develops and commercializes therapies for rare diseases. Its initial franchise addresses hyperphagia, the persistent and potentially life-threatening hunger associated with Prader-Willi syndrome.
VYKAT XR
VYKAT XR is a once-daily extended-release formulation of diazoxide choline approved in the United States for hyperphagia in adults and children age four and older with Prader-Willi syndrome. It is the company’s first commercial product.
International Expansion
Soleno has begun building a commercial patient and prescriber base in the United States and has submitted a European marketing application. The company plans to use the U.S. launch infrastructure and disease-community relationships to support expansion into additional territories.
今後のカタリスト
- Soleno’s catalysts are DCCR in Prader-Willi syndrome and the next regulatory / commercialization steps around that program. The stock is still driven by whether the rare-disease opportunity can keep advancing.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。